Safe disposal of prescription drugs is turning out to be a costly endeavor, and the pharmaceutical industry seems to want no part of it.
Safe disposal of prescription drugs is turning out to be a costly endeavor, and the pharmaceutical industry seems to want no part of it.
The National Take-Back Initiative, a biannual event coordinated by the Drug Enforcement Administration (DEA), was launched in September 2010—a venture meant to allow the safe disposal of prescription medications and avoid misuse as well as unwanted environmental effects—a danger associated with flushing these medications into the water streams. Since then, the DEA has been working with the Congress to install more permanent regulations, such as the Safe and Secure Drug Disposal Act of 2010.
But drug disposal costs money, costs that pharmaceutical manufactures do not want to bear. Local governments—such as Alameda County and the city of San Francisco—have taken the initiative to pass ordinance that requires drug manufacturers who have at least 1 prescription medication or over-the-counter (OTC) medicines for sale in their city or county, to participate in stewardship programs for safe disposal. According to STAT, Alameda County estimated the annual costs at $330,000, while the trade group PhRMA estimated the costs could cross $1 million.
STAT reports that the industry has now brought lobbying to the local level, after the US Supreme Court overruled their objections. A national trade association that represents manufacturers of OTC medications and dietary supplements, started calling residents of Los Angeles County warning them of a tax hike due to the take-back program. Another approach is forcing the local governments to implement a state-run and funded program for the collection and disposal of hazardous waste.
One such bill (Assembly Bill 45), introduced in the California state assembly, was amended in January this year to reflect the changes. Some of the trade groups have proposed to fund a nonprofit organization at $1 million annually over a 5-year period, to educate consumers in California on appropriate handling and disposal of drugs. This is only if local governments commit to managing and funding the actual disposal.
Meanwhile, As You Sow, a nonprofit, recently sent a letter on behalf of 22 investment firms addressing the CEOs of 10 major pharmaceutical companies, to provide shareholders with a policy statement on the take back program. “We hope you will work with industry peers to develop policies leading to a national drug take back program, and provide primary financial responsibility for the program. We believe it’s time for the industry to manage the end of life portion of the product life cycle in the same manner that it manages design and marketing of its goods and services,” the letter states.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Mediterranean Diet and Exercise Improve Outcomes in MASLD, MASH
August 29th 2025The Mediterranean diet and aerobic exercise significantly reduced weight, liver enzymes, and waist circumference in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), a study finds.
Read More